- Home
- ORIC vs XNCR Comparison
ORIC vs XNCR Comparison
Compare ORIC & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORIC | XNCR |
|---|---|---|
| Founded | 2014 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 861.3M | 881.9M |
| IPO Year | 2020 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ORIC | XNCR |
|---|---|---|
| Price | $8.30 | $11.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 9 |
| Target Price | $19.73 | ★ $22.33 |
| AVG Volume (30 Days) | ★ 1.2M | 734.1K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 19.67 | ★ 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.80 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $5.51 | $6.92 |
| 52 Week High | $14.93 | $18.69 |
Technical Indicators
Market Signals| Indicator | ORIC | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 37.06 | 42.24 |
| Support Level | $7.90 | $11.02 |
| Resistance Level | $11.22 | $13.28 |
| Average True Range (ATR) | 0.44 | 0.72 |
| MACD | -0.01 | -0.16 |
| Stochastic Oscillator | 30.75 | 24.53 |
Price Performance
Historical ComparisonAbout ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.